Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 15/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091763 | 0.80 | ALDH1A1 (0.49) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10091762 | 0.80 | AOC3 (0.43) | LMNAARSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29957592 | 0.79 | AOC3 (0.43) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10091760 | 0.79 | SMN1; SMN2 (0.36) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2559694 | 0.78 | SMN1; SMN2 (0.41) | LMNANPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL4145551 | 0.77 | LMNA (0.58) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17266277 | 0.75 | AR (0.61) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10091761 | 0.75 | CYP3A4 (0.43) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL24375919 | 0.74 | LMNA (0.58) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2698786 | 0.74 | NPC1 (0.60) | LMNAARNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2588107-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | Takeda Pharmaceutical Company Limited (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| EP-2313407-A1 | cMET INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | HGF, MET, HGFAC | LMNA 4523/4885AR 2173/4885NPC1 1589/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | LMNA 3512/4885AR 3309/4885NPC1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.